Similarly, binding of TIGIT on T cells to CD155 on tumor cells and APCs can downregulate activation of ZAP70 and NF-κB in T cell intracellular signaling, which in turn inhibits T cell activation (Liu et al., 2022). Here, PVR is linked to neoplasm.